IonQ: The Future Won’t Wait—We’re Building It
IonQ is forging a path in quantum computing that doesn’t just promise breakthroughs—it guarantees an ecosystem. Here’s how their strategic partnerships are reshaping industries and setting the stage for quantum's practical revolution.
Hyundai Motor Company: Driving Innovation into the Future
Hyundai and IonQ are redefining what’s possible for autonomous vehicles and battery tech. Machine vision algorithms? Check. Electrochemical simulation for next-gen batteries? Double check.
Forget electric vehicle hype. The real race is quantum-powered autonomy, and IonQ is putting Hyundai in pole position.
"Batteries power cars; quantum powers the future."
U.S. Air Force Research Lab: Securing the Quantum Advantag
A $54.5M contract speaks volumes. IonQ is working with AFRL to push boundaries in quantum networking and secure communications.
If quantum is the new arms race, IonQ is the defense contractor of the future, weaponizing algorithms and hardware for tomorrow’s battlefields.
"Quantum communication isn’t a luxury; it’s a necessity in the age of cyber warfare."
General Dynamics Information Technology: Quantum Meets Government
IonQ and GDIT are collaborating to craft quantum go-to-market strategies, targeting government sectors—a critical area for innovation and funding. As a subsidiary of General Dynamics (GD), GDIT strengthens IonQ's position in leveraging government contracts, a proven pathway for quantum startups to scale and achieve long-term dominance.
"Tech revolutions start where strategy meets funding—just ask NASA or DARPA."
University of Maryland: Quantum's Academic Vanguard
A $9M collaboration with UMD’s National Quantum Lab cements IonQ’s role in quantum research and education.
Quantum computing needs thinkers before doers. This partnership ensures the next generation of researchers cut their teeth on IonQ systems.
"Academia doesn’t just study revolutions—it starts them."
QuantumBasel: A European Quantum Beachhead
Deploying systems in Switzerland, IonQ is making quantum local for Europe. The data center initiative is a gateway to European markets.
Why wait for Europe to come to quantum when you can bring quantum to Europe? This is how global markets are won.
"Proximity isn’t just geographical—it’s strategic."
AstraZeneca: Redefining Drug Discovery
Partnering on quantum use cases in drug discovery, IonQ is unlocking faster, more efficient ways to revolutionize healthcare.
Healthcare isn’t about treating diseases—it’s about eliminating them. Quantum is the scalpel AstraZeneca needs.
"The cure for complexity is quantum simplicity."
Ansys: Quantum-Enhanced Engineering Simulations
Quantum technology is being integrated into engineering designs, promising faster, more accurate simulations.
Engineering is no longer bound by classical constraints. IonQ and Ansys are making the impossible seem inevitable.
"Design isn’t just form and function; it’s innovation and iteration."
Imec & NKT Photonics: Quantum Hardware on Steroids
Building next-gen Photonic Integrated Circuits and laser systems, IonQ is turbocharging quantum scalability.
Hardware is the backbone of any quantum revolution. IonQ’s focus here ensures it can scale up faster than competitors.
"The quantum race isn’t won by speed alone—it’s won by scalability."
South Korea: A Quantum Trifecta
Collaborations with Hyundai, Seoul National University, and Sungkyunkwan University focus on batteries, materials, and autonomous tech.
South Korea doesn’t dabble—it dominates. These partnerships ensure IonQ is part of Asia’s tech supremacy.
"Innovation thrives where ambition meets collaboration."
Accenture Federal Services & Q-CTRL: Precision Quantum
Improved anomaly detection with quantum computing proves the value of collaborative precision.
When three leaders team up, anomalies don’t stand a chance. This is practical quantum at its finest.
"The quantum revolution is precise, and precision is profitable."
Big Picture: Partnerships aren’t just a strategy; they’re IonQ’s foundation. From defense to healthcare to academia, IonQ is embedding itself in industries that matter most.
Want to see how quantum fits into your portfolio? Start following IonQ now.
Astrazeneca
AZN AstraZeneca PLC Options Ahead of EarningsAnalyzing the options chain and the chart patterns of AZN AstraZeneca PLC prior to the earnings report this week,
I would consider purchasing the 80usd strike price Calls with
an expiration date of 2024-7-26,
for a premium of approximately $1.23.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
AZN AstraZeneca PLC Options Ahead of EarningsAnalyzing the options chain and the chart patterns of AZN AstraZeneca PLC prior to the earnings report this week,
I would consider purchasing the 66usd strike price in the money Puts with
an expiration date of 2023-11-10,
for a premium of approximately $2.30.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
AZN To Test Yearly Pivot Support AstraZeneca marginally eclipsed its prior cycle highs through the 72.00 level before pulling back to suggest a potential weekly double top pattern, however, I would highlight the lack of momentum divergence at this point, which suggests to me that the current retreat is corrective. On the four-hour time frame, we can clearly see an interim 5-wave sequence has been completed, I am now looking for a corrective cycle to unfold that ultimately tests and hold the yearly pivot point at the 64.00 area, from hear I will be looking for bullish reversal patterns to re-engage long exposure to target are retest and break of the prior cycle highs through 72.00 to challenge the weekly projected trend channel support towards the 76.00 level. A loss of the yearly pivot support on a daily closing basis would suggest a deeper correction is likely to unfold opening a test of the weekly high-volume node and projected trend channel support at the 55/56.00 area.
ARDS first Investor call of 2022. Phase 3 news ???Aridis Pharmaceuticals announced first Investor call of 2022 for today, after the closing bell.
Exiting pipeline with 2 phase 3 drugs and their monoclonal antibody cocktail.
AstraZeneca PLC (AZN) has a stake in this company.
CEO has co-developed several drug which have been sold to Astra Zeneca, Megabits and MedImmune.
Aridis Pharmaceuticals can be a potential buyout for AZN.
Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment!
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
Market Cap of only 22.48Mil
52 Week Range 1.13 - 8.4
Euro falls to 4-mth low despite strong PMIsThe euro continues to head south in Wednesday trading. Currently, EUR/USD is trading at 1.1828, down 0.17% on the day.
Just four weeks ago, EUR/USD was basking above the 122 level and looking strong against the US dollar. Fast forward to the present, and the euro is struggling to keep above the 1.18 level as its trades at its lowest level since November 23rd. It's been a dreadful March, with EUR/USD falling 2 percent this month. The main catalyst for the slide against the US dollar has been the significant rise in US Treasury yields, which have boosted the dollar. US 10-year yields rose to 1.73% on Friday, as shade below its 52-week high of 1.75%. If the upward trend resumes, we can expect the euro to lose more ground.
Investor sentiment towards the eurozone has been weak, to such an extent that excellent PMI data on Wednesday failed to give the euro a much-needed boost. On the manufacturing front, France, Germany and the eurozone all showed strong growth, highlighted by an outstanding German read of 66.6. Services also showed improvement, although France and the eurozone remain in contraction territory. German Services PMI improved to 50.8, the first time the index has shown growth in seven months.
The euro is also under pressure this week over a vaccine dispute with the EU. A shortage of AstraZeneca vaccines across Europe has resulted in a threat by the EU to block shipments of the vaccine to the UK. Such a move would likely send tense relations between the EU and the UK to a new low. The irony of the EU move to hoard vaccines has not been lost in British media, with The Telegraph newspaper publishing a survey which shows that a majority of people in Germany, France, Italy and Spain consider the AstraZeneca vaccine as unsafe.
EUR has broken below critical support at 1.1840, where the 200-DMA is also situated. If EUR closes below this level, we can expect further losses, with the next support line at 1.1808. If the downturn continues, it could potentially reach as low as the 1.16 level in the coming days. On the upside, 1.1971 has some breathing room in resistance as EUR loses ground.
Bullish Signals for AstraZenecaFundamental analysis
In the UK, more than a million people have already been vaccinated with this relatively simple vaccine. It won't be long before AstraZeneca has done its administration and the whole world (starting with Europe) will use their relatively cheap product.
Technical Analysis
1. Trend breakout
2. High Volume
3. Next Target is 70
AstraZeneca, too, aboard the choo choo train of drops.NASDAQ:AZNAgain a bearish pharma stock, and has been for a while like the rest. Seeing zigzags here again and seeing us descend lower to one or more Fibonacci projections I traced. Not financial advice, but I will leave with saying that any short is always riskier and I never trade against the trend. Good luck!
PCI Biotech $PCIB bullish breaching 100EMA coming into Q4* Norwegian Drug Delivery Platform Biotech operating within the Oslo Cancer Cluster
* Notoriously volatile norwegian small cap with large amount of stock held by enthusiastic retail investor crowd.
* Ongoing research collaboration with AstraZeneca recently concluded, longs betting on partnership deal incoming.
* Stock typically rallies ahead of quarterly reports and experiences sell the news events.
* Norwegian biotech flying at All Time High valuations after recent Vaccibody partnership with Genentech.